Bionime Corporation (TPE:4737)

Bionime Statistics

Total Valuation

Bionime has a market cap or net worth of TWD 3.84 billion. The enterprise value is 6.02 billion.

Market Cap	3.84B
Enterprise Value	6.02B

Important Dates

The next estimated earnings date is Monday, August 10, 2026.

Earnings Date	Aug 10, 2026
Ex-Dividend Date	n/a

Share Statistics

Bionime has 67.29 million shares outstanding. The number of shares has increased by 3.18% in one year.

Current Share Class	67.29M
Shares Outstanding	67.29M
Shares Change (YoY)	+3.18%
Shares Change (QoQ)	+9.04%
Owned by Insiders (%)	8.63%
Owned by Institutions (%)	0.69%
Float	38.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.18
PB Ratio	1.74
P/TBV Ratio	3.00
P/FCF Ratio	16.50
P/OCF Ratio	10.91
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-24.31
EV / Sales	3.42
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	25.86

Financial Position

The company has a current ratio of 0.85, with a Debt / Equity ratio of 1.15.

Current Ratio	0.85
Quick Ratio	0.49
Debt / Equity	1.15
Debt / EBITDA	n/a
Debt / FCF	10.98
Interest Coverage	-4.34

Financial Efficiency

Return on equity (ROE) is -11.98% and return on invested capital (ROIC) is -6.37%.

Return on Equity (ROE)	-11.98%
Return on Assets (ROA)	-3.05%
Return on Invested Capital (ROIC)	-6.37%
Return on Capital Employed (ROCE)	-7.12%
Weighted Average Cost of Capital (WACC)	3.04%
Revenue Per Employee	3.52M
Profits Per Employee	-495,270
Employee Count	500
Asset Turnover	0.31
Inventory Turnover	2.17

Taxes

Income Tax	-89.18M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -14.55% in the last 52 weeks. The beta is -0.09, so Bionime's price volatility has been lower than the market average.

Beta (5Y)	-0.09
52-Week Price Change	-14.55%
50-Day Moving Average	62.68
200-Day Moving Average	61.48
Relative Strength Index (RSI)	43.58
Average Volume (20 Days)	113,749

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bionime had revenue of TWD 1.76 billion and -247.64 million in losses. Loss per share was -3.59.

Revenue	1.76B
Gross Profit	569.90M
Operating Income	-277.44M
Pretax Income	-335.08M
Net Income	-247.64M
EBITDA	-122.71M
EBIT	-277.44M
Loss Per Share	-3.59

Balance Sheet

The company has 387.48 million in cash and 2.55 billion in debt, with a net cash position of -2.17 billion or -32.21 per share.

Cash & Cash Equivalents	387.48M
Total Debt	2.55B
Net Cash	-2.17B
Net Cash Per Share	-32.21
Equity (Book Value)	2.21B
Book Value Per Share	30.03
Working Capital	-266.38M

Cash Flow

In the last 12 months, operating cash flow was 352.16 million and capital expenditures -119.38 million, giving a free cash flow of 232.79 million.

Operating Cash Flow	352.16M
Capital Expenditures	-119.38M
Depreciation & Amortization	154.73M
Net Borrowing	-561.08M
Free Cash Flow	232.79M
FCF Per Share	3.46

Margins

Gross margin is 32.34%, with operating and profit margins of -15.74% and -14.05%.

Gross Margin	32.34%
Operating Margin	-15.74%
Pretax Margin	-19.01%
Profit Margin	-14.05%
EBITDA Margin	-6.96%
EBIT Margin	-15.74%
FCF Margin	13.21%

Dividends & Yields

Bionime does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.18%
Shareholder Yield	-3.18%
Earnings Yield	-6.45%
FCF Yield	6.06%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 8, 2025. It was a forward split with a ratio of 1.0998680158.

Last Split Date	Sep 8, 2025
Split Type	Forward
Split Ratio	1.0998680158

Scores

Altman Z-Score	n/a
Piotroski F-Score	4